Neuro aktuell

Ausgabe 7-2020

Literatur

Schwerpunkt: Spinale Muskelatrophie

Titel: Therapeutische Optionen bei erwachsenen Patienten mit spinaler Muskelatrophie (S. 7–13)

Autorin: D. Lindner, C. Kleinschnitz, T. Hagenacker

Literatur:

1. Farrar MA & Kiernan MC. The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics 2015; 12(2): 290–302

2. Lefebvre S et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80(1): 155–165

3. Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007; 22(8): 946–951

4. Lorson CL et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96(11): 6307–6311

5. Mailman MD et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4(1): 20–26

6. Crawford TO et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 2012; 7(4): e33572

7. Castro D & Iannaccone ST. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol 2014; 16(11): 316

8. Finkel RS et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017; 377(18): 1723–1732

9. Mercuri E et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med 2018; 378(7): 625–635

10. European Medicines Agency, Assessment Report Spinraza https://www.ema.europa.eu/en/documents/assessment-report/spinraza-epar-public-assessment-report_en.pdf [letzter Zugriff: 08.09.20 um 17:35]

11. Hagenacker T et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 2020; 19(4): 317–325

12. Wurster CD et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. J Neurol 2019; 266(1): 183–194

13. Kizina K et al. Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy. Front Neurol 2019; 10: 1166. Published 2019 Nov 5

14. Strauss KA et al. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy. J Pediatr Orthop 2018; 38(10): e610–e617

15. Kirschner J et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy [published online ahead of print, 2020 Jul 9]. Eur J Paediatr Neurol 2020; S1090–3798(20)30142–2

16. Ziegler A et al. Handlungsempfehlungen zur Gentherapie der spinalen Muskelatrophie mit Onasemnogene Abeparvovec – AVXS-101: Konsensuspapier der deutschen Vertretung der

Gesellschaft für Neuropädiatrie (GNP) und der deutschen Behandlungszentren unter Mitwirkung des Medizinisch-Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke (DGM) e. V. Nervenarzt 2020; 91(6): 518–529

17. Wang D et al. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18(5): 358–378

18. Mendell JR et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med 2017; 377(18): 1713–1722

19. Lowes LP et al. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatr Neurol 2019; 98: 39–45

20. Mendell J et al. AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones Neurology 2018; 90: 29.001

21. Foust KD et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28(3): 271–274

22. Jędrzejowska M & Kostera-Pruszczyk A. Spinal muscular atrophy – new therapies, new challenges. Neurol Neurochir Pol 2020; 54(1): 8–13

23. Novartis Media Release: https://www.novartis.com/news/media-releases/novartis-announces-avxs-101-intrathecal-study-update [letzter Zugriff: 27.08.20 um 11:00 Uhr]

24. European Medicines Agency, Zolgensma: EPAR – Product information: https://www.ema.europa.eu/en/documents/product-information/zolgensma-epar-product-information_en.pdf [letzter Zugriff: 26.08.20 um 11:30 Uhr]

25. Poirier A et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect 2018; 6(6): e00447. Published 2018 Nov 29

26. Roche Media Release: https://www.roche.com/dam/jcr:916a6937-413a-47b5-9e0e-ac4cad70c71b/en/roche-media-release-230120.pdf [letzter Zugriff: 27.08.20 um 11:00 Uhr]

27. https://neurologienetz.de/fachliches/erkrankungen/neuro-muskulaere-erkrankungen/spinale-muskelatrophien#c3618 [letzter Zugriff: 27.08.20 um 11:00 Uhr]

Schwerpunkt: Kopfschmerz

Titel: Alkoholinduzierter Kopfschmerz – Pathogenese und Strategien der Prävention (S. 30–35)

Autorin: J. Bielenberg

Literatur:

1. Verster JC, Vermeulen SA, Loo AJAEV, et al. Dietary Nutrient Intake, Alcohol Metabolism, and Hangover Severity. J Clin Med 2019; 8(9): 1316

2. Goodsell DS. Molecule of the Month: Alcohol Dehydrogenase. 2001. (https://pdb101.rcsb.org/motm/13). Zugegriffen: 10.08.2020

3. Kagi JH, Vallee BL. The role of zinc in alcohol dehydrogenase. V. The effect of metal-binding agents on the structure of the yeast alcohol dehydrogenase molecule. J Biol Chem 1960; 235: 3188–3192

4. Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G. Alcoholic disease: liver and beyond. World J Gastroenterol 2014 Oct 28; 20(40): 14652–14659

5. Stephens R, Ling J, Heffernan TM, Heather N, Jones K. A review of the literature on the cognitive effects of alcohol hangover. Alcohol Alcohol 2008; 43(2): 163–170

6. Swift R, Davidson D. Alcohol hangover: mechanisms and mediators. Alcohol Health Res World 1998; 22(1): 54–60

7. Wiese JG, Shlipak MG, Browner WS. The alcohol hangover. Ann Intern Med 2000; 132(11): 897–902

8. Maxwell CR, Spangenberg RJ, Hoek JB, Silberstein SD, Oshinsky ML. Acetate causes alcohol hangover headache in rats. PLoS One 2010; 5(12): e15963

9. Van de Loo A, Mackus M, Korte-Bouws G, Brookhuis K, Garssen J, Verster J. Urine ethanol concentration and alcohol hangover severity. Psychopharmacology (Berl) 2017; 234(1): 73–77

10. Kim MJ, Lim SW, Kim JH, Choe DJ, Kim JI, Kang MJ. Effect of Mixed Fruit and Vegetable Juice on Alcohol Hangovers in Healthy Adults. Prev Nutr Food Sci 2018; 23(1): 1–7

11. Hong YH. Effects of the herb mixture, DTS20, on oxidative stress and plasma alcoholic metabolites after alcohol consumption in healthy young men. Integr Med Res 2016; 5(4): 309–316

12. Varella Morandi Junqueira-Franco M, Ernesto Troncon L, Garcia Chiarello P, do Rosário Del Lama Unamuno M, Afonso Jordao A, Vannucchi H. Intestinal permeability and oxidative stress in patients with alcoholic pellagra. Clin Nutr 2006; 25(6): 977–983

13. Narasimha VL, Ganesh S, Reddy S, et al. Pellagra and Alcohol Dependence Syndrome: Findings from a Tertiary Care Addiction Treatment Centre in India. Alcohol Alcohol 2019; 54(2): 148–151

14. Li Q, Xie G, Zhang W, et al. Dietary nicotinic acid supplementation ameliorates chronic alcohol-induced fatty liver in rats. Alcohol Clin Exp Res 2014; 38(7): 1982–1992

15. Li H, Hallows WH, Punzi JS, Pankiewicz KW, Watanabe KA, Goldstein BM. Crystallographic studies of isosteric NAD analogues bound to alcohol dehydrogenase: specificity and substrate binding in two ternary complexes. Biochemistry 1994; 33(39): 11734–11744